Jeffrey S. Miller

发表

Matching at HLA-C improved the outcomes after double umbilical cord blood transplantation for recipients of 2–4/6 HLA-matched grafts

J. Wagner, K. Ballen, R. Soiffer, 2017 .

FLT-3 Ligand and Marrow Stroma-Derived Factors Promote CD 3 g , CD 3 d , CD 3 z , and RAG-2 Gene Expression in Primary Human CD 34 1 LIN 2 DR 2 Marrow Progenitors

P. Gaffney, Jeffrey S. Miller, J. Lund, 1998 .

Intraperitoneal delivery of human natural killer cells for treatment of cancer in a mouse xenograft model.

D. Kaufman, M. Geller, D. Knorr, 2013 .

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy for Relapsed Hematologic Malignancies Postallogeneic Hematopoietic Cell Transplantation

D. Weisdorf, B. Blazar, M. Verneris, 2014 .

Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis

J. Wagner, M. MacMillan, B. Hirsch, 2007, American journal of hematology.

Mouse fetal and embryonic liver cells differentiate human umbilical cord blood (UCB) progenitors into CD56 negative NK cell precursors in the absence of IL-15

J. Wagner, R. Oostendorp, T. Lutz, 2008 .

Prevention of GVHD by adoptive T regulatory therapy is associated with active repression of peripheral blood toll-like receptor-5 mRNA expression Biol Blood Marrow Transplant

C. Meisel, K. Vogt, B. Blazar, 2014 .

NK cell killing of AML and ALL blasts by Killer-Immunoglobulin Receptor (KIR) negative NK cells after NKG2A and LIR-1 blockade Marrow

V. Bachanova, M. Gleason, M. Verneris, 2010 .

Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

J. Wagner, J. Tolar, C. Rooney, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma

U. Höpken, A. Rehm, K. Malmberg, 2022, Nature Communications.

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.

F. Gao, P. Westervelt, J. Dipersio, 2021, Blood.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

Christof von Kalle, Jakub Tolar, Richard Gabriel, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Novel cell and immune engagers in optimizing tumor specific immunity post autologous transplant in multiple myeloma.

V. Bachanova, M. Janakiram, Nivedita Arora, 2021, Transplantation and cellular therapy.

Myelodysplastic syndrome after autologous transplant for lymphoma [7]

J. Vose, James R. Anderson, A. Kessinger, 1994 .

The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells

M. Verneris, Jeffrey S. Miller, 2009, British journal of haematology.

Therapy for chronic myelogenous leukemia with marrow transplantation

Jeffrey S. Miller, Philip B. McGlave, 1993, Current opinion in oncology.

High Proliferating Regulatory T cells Post-transplant are Associated with Poor Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation: Regulatory T cells and Autologous Hematopoietic Stem Cell Transplantation in Lymphoma.

V. Bachanova, Q. Cao, C. Brunstein, 2022, Transplantation and cellular therapy.

CMV Triplex vaccine to enhance adaptive NK and T-cell reconstitution after autologous hematopoietic cell transplantation.

D. Weisdorf, A. Rashidi, D. Diamond, 2022, Transplantation and cellular therapy.

A multicenter phase 2 clinical trial of 10-day decitabine, dose-escalated donor lymphocyte infusion, and ruxolitinib for relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic cell transplantation.

J. Dipersio, D. Weisdorf, A. Rashidi, 2023, Transplantation and cellular therapy.

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies

F. Cichocki, Jeffrey S. Miller, Sjoukje J C van der Stegan, 2022, Blood.

Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-Versus-Host Disease.

M. MacMillan, D. Weisdorf, B. Blazar, 2023, Transplantation and cellular therapy.

Promoting T and NK cell attack: preserving tumor MICA/B by vaccines

Jeffrey S. Miller, Frank Cichocki, 2022, Cell Research.

Physicochemical Mechanisms of Protection Offered by Agarose Encapsulation during Cryopreservation of Mammalian Cells in the Absence of Membrane-Penetrating Cryoprotectants.

A. Aksan, D. McKenna, Mian Wang, 2023, ACS applied bio materials.

Generation and Large‐Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft‐Versus‐Host Disease

J. Wagner, C. June, B. Blazar, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

Beau R. Webber, C. von Kalle, D. Voytas, 2016, Molecular Therapy.

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

F. Marincola, S. Rosenberg, M. Kalos, 2012, Journal of Translational Medicine.